Web23 sep. 2024 · Inclusion Criteria: Satisfactory completion of ION-682884-CS3 (NCT04136184) (Index Study) as judged by the Investigator and Sponsor, or diagnosis of hATTR-PN and satisfactory completion of either study ISIS 420915-CS101 or study 2024-P001436 (NCT03702829) (both are Investigator-Sponsored studies with inotersen - the … WebDesign and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L Rx (ION-682884-CS3) in Hereditary Transthyretin …
Design and Rationale of the Global Phase 3 NEURO-TTRansform …
Web1. Satisfactory completion of ION-682884-CS3 as judged by the Investigator and Sponsor, OR diagnosis of hATTR-PN and satisfactory completion of either study ISIS 420915-CS101 or study 2024-P001436 (both are Investigator-Sponsored studies with inotersen - the unconjugated version of ION-682884) as judged by the Investigator and Sponsor 2. WebDesign and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin … can cat scabies be transmitted to humans
Design and Rationale of the Global Phase 3 NEURO-TTRansform …
Web17 jul. 2024 · NEURO-TTRansform: a study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with hereditary transthyretin-mediated amyloid polyneuropathy (NCT04136184). ClinicalTrials.gov. Updated June 10, 2024. Accessed July 17, 2024. 11. Web2 nov. 2024 · Participants received ION-682884 matching placebo, subcutaneously (SC) once every 4 weeks [Q4W] (total of 4 doses) along with daily oral supplemental doses of … WebION-682884 reduces the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in participants blood may reduce the amount of … can cat scans be harmful